Development of a protease-resistant ADAMTS13 to improve stability against proteolytic degradation

Development of a protease-resistant ADAMTS13 to improve stability against proteolytic degradation

Abstract: Recombinant ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) was recently approved by the US Food and Drug Administration for the treatment of heritable thrombotic thrombocytopenic purpura, and preclinical studies have demonstrated its efficacy i...

Full description

Saved in:
Bibliographic Details
Main Authors: Veronica DeYoung, Rex Huang, Hasam Madarati, Rida Malik, Peter Andrisani, Cherie Teney, Colin A. Kretz
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925001879
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items